theheart.org: Interventional Surgery news and studies. Duke and Mayo partnership.

Interventional/Surgery

PCI in Left Main Disease: Are We There Yet?

1 COMMENT - Nov 11, 2009 11:41 EST

SYNTAX and MAIN-COMPARE suggest a role for PCI in subsets of patients with left main disease; however, in current ACC/AHA guidelines this remains a class III indication. Dr. Turco chairs a roundtable with interventionalists Drs Kandzari and Park and surgeon Dr Sabik.

Interventional/Surgery

TAVI vs AVR Patient Selection

Oct 27, 2009 14:49 EDT

The PARTNER and PAVIS trials of transcatheter aortic valve implementation will include inoperable or very high-surgical-risk patients. In Europe, where the devices have been approved for a few years, the technology is being expanded to lesser-risk patients. Interventionalist Dr Jeffrey Popma discusses the selection of patients with surgeon Dr Mathew Williams.

Interventional/Surgery

Emerging Stent Technologies: Adding Innovation and New Science to Clinical Practice

Oct 20, 2009 13:38 EDT

Dr. Dean Kereiakes leads an international panel of experts, Drs. Meredith, Banning, and Hermiller, as they discuss fascinating developments in stent and polymer technology and design their "dream stent."

Interventional/Surgery

Drug-Eluting Stents: Head-to-Head Clinical Trial Results

Oct 16, 2009 11:06 EDT

How do drug-eluting stents compare? Our panel of experts, Drs. Stone, Kereiakes, Serruys, and Windecker discuss the late-breaking trials at TCT 2009 of DES vs DES.

Interventional/Surgery

Revascularization in Patients With Diabetes

Oct 7, 2009 14:12 EDT

Since BARI, CABG has been the gold standard for patients with diabetes and multivessel disease. However, SYNTAX suggests an increasing role for PCI and BARI 2D highlights the importance of optimal medical therapy. Dr. Boden leads a multidisciplinary discussion with Drs. Holmes and Taggart.

Interventional/Surgery

Dual Antiplatelet Therapy: Dueling Options in Real-World Practice

2 COMMENTS - Sep 30, 2009 13:31 EDT

With the recent approval of a third-generation thienopyridine, choice of agent can be added to the list of considerations in the management of ACS patients, as well as the appropriate timing and dosing of thienopyridine. Using some case vignettes, Dr. King leads a discussion with Drs. Bhatt and Steg on their clinical decision-making.

Acute Coronary Syndromes

Antiplatelet Therapy: A Brazilian Expert's Take

1 COMMENT - Jul 14, 2009 12:00 EDT

From SOLACI 2009 in Rio de Janeiro. Dr. Mahmud hears how Dr. Feres interprets the data on antiplatelet/antithrombin strategies for his practice in Brazil.

Interventional/Surgery

Transcatheter Aortic Valves: Lessons From Europe

Jun 26, 2009 00:02 EDT

Transcatheter aortic valve implantation (TAVI) has been approved in Europe since 2007, whereas these devices are just entering large-scale research trials in the United States. Dr. Popma leads a panel discussion with European interventionalist Dr. Eberhard Grube and surgeon Dr. Neil Moat on their experiences with TAVI.

Clinical cardiology

New Data on Polyvascular Disease and ACS

1 COMMENT - Jun 23, 2009 09:40 EDT

Recently published data suggest that prior polyvascular disease increases the risk for inhospital adverse events in patients with ACS. Join Drs. Deepak Bhatt, Jean-Pierre Bassand, and José R. Gonzalez-Juanatey for a discussion of the current data on identification and management of patients with polyvascular disease.

Interventional/Surgery

DES and PCI: Endurance and New Frontiers

3 COMMENTS - Jun 23, 2009 00:45 EDT

Given SYNTAX, is left main stenting ready for primetime? Do the NCDR data lay to rest DES safety concerns? Recorded at EuroPCR 2009, Dr. Popma discusses the current status and future roles of PCI and DES with Drs.Gershlick and Tamburino.

Interventional/Surgery

There's Triple Vessel Disease and Triple Vessel Disease: Risk Assessment

2 COMMENTS - Jun 22, 2009 08:08 EDT

How do the results of the SYNTAX trial impact clinical practice now? Join Drs. Banning and Hill as they present a complex case taken directly from the SYNTAX trial and discuss how new data will impact their choice of treatment, and listen to an overview of the trial presented by Dr. William Wijns.

Clinical cardiology

Combination Therapy and Cardiovascular Events: A Neurologist's Perspective

1 COMMENT - Jun 17, 2009 11:48 EDT

AF can lead to stroke, congestive heart failure, and other serious complications. Successful management should include reducing these risks. Join our expert panel, Drs. Peter Rothwell, Donald Easton, and Mark Alberts, as they discuss new data and strategies for improving outcomes in patients with AF.

Clinical cardiology

2009 Antiplatelet Debate: What's New in ACS

6 COMMENTS - Jun 12, 2009 15:03 EDT

Despite modern therapy, the rates of death, MI, bleeding, and readmission remain high in patients with ACS. Join Drs. Jeffery Popma, Héctor Bueno, Freek Verheugt, and Sunil. Rao for a review of the latest data on antiplatelet therapy for patients with ACS.

Interventional/Surgery

Variable Rate Contrast Injection in the Cath Lab

7 COMMENTS - May 11, 2009 10:00 EDT

Variable rate contrast delivery systems have the potential to improve workflow and patient outcomes by providing a more precise flow of contrast. Watch Dr. Jeffrey Moses and his team as they demonstrate the use of the device in the cath lab in a patient with complex lesions.

Interventional/Surgery

Complex Lesions and the Dynamics of Patient Care: Putting the Puzzle Together

1 COMMENT - Apr 21, 2009 12:00 EDT

Surgery? PCI? How do we choose the optimal therapy for any given patient? Join our panel of experts, Drs. Feldman, Cohen, Kereiakes, Leon, and Mohr as they discuss latest data on treating complex lesions.

Acute Coronary Syndromes

ACC 2009: Emerging Insights Into Early Use of Antithrombotic Therapy in NSTEMI Patients

1 COMMENT - Apr 20, 2009 12:00 EDT

Join Dr. Newby for a discussion of new data on antithrombotic choices and management of NSTEMI patients.

Interventional/Surgery

Assessing Long-term Risks & Benefits of DES and BMS

2 COMMENTS - Apr 20, 2009 00:00 EDT

When choosing between DES and BMS or among the various DES, how much weight should be given to 1-year data vs the totality of evidence? What is the duration of stent thrombosis risk? Dr. Leon leads a panel discussion to address these issues with Drs. Kandzari and Yeung.

Interventional/Surgery

Thoracic Aneurysms: Open vs Endovascular Approaches

2 COMMENTS - Apr 20, 2009 00:00 EDT

Learn about the current status of less-invasive strategies to repair thoracic aneurysms as Dr. Mack leads a discussion with vascular surgeons, Drs. Kasirajan and Woo. Which cases are amenable to endovascular repair and which require open surgery?

Acute Coronary Syndromes

Antiplatelet Options for ACS: The Changing Landscape

Feb 12, 2009 09:00 EST

On February 3, 2009, the FDA's Cardiovascular and Renal Drugs Advisory Committee unanimously voted to recommend approval of the novel thienopyridine prasugrel for use in ACS patients undergoing PCI. Drs. Nissen, Ohman, Kandzari, Topol, and Steg each give their take on the likely implications for clinical practice and remaining issues of concern in the optimal management of patients with ACS.

Clinical cardiology

Balancing the Benefit and Risk of Antiplatelet Therapy in Clinical Practice

4 COMMENTS - Dec 4, 2008 10:08 EST

Several recent studies have demonstrated that patients with atherothrombosis who experience bleeding may be at increased risk for long-term adverse ischemic events. Whereas the specific mechanism(s) that may explain the correlation between bleeding and ischemic events remains to be fully elucidated, these findings may have important ramifications for the selection of appropriate antiplatelet therapy. Drs. Berger, Mehta, Simon, Steg, and White discuss.

Clinical cardiology

Antiplatelet Therapy in Atherothrombotic Disease

1 COMMENT - Dec 3, 2008 09:00 EST

Harmonizing guideline recommendations for antiplatelet therapy with recent clinical trial data and concerns about bleeding can pose a challenge. Drs Berger, Mehta, Simon, Steg, and White each give presentations addressing issues relating to the appropriate use of antiplatelet therapy in patients with atherothrombotic disease

Interventional/Surgery

Optimal Acute Myocardial Infarction Management Redefined

11 COMMENTS - Dec 1, 2008 10:30 EST

Can drug-eluting stents now be considered the standard of care in patients with STEMI undergoing PCI? Can target lesion revascularization be reduced further? What about bleeding? Please join Drs Stone, White, and Harrington as they tackle these and other pressing questions in the treatment of AMI.

Clinical cardiology

Antiplatelet Therapy for the Prevention of Stroke in AF

18 COMMENTS - Nov 26, 2008 09:53 EST

Warfarin remains the cornerstone of stroke prevention in patients with AF. However, many patients are unable or unwilling to take it. Could antiplatelet therapy fill this gap? How might investigational anticoagulants change the playing field? Dr Naccarelli leads a panel discussion with Drs Connolly and Camm.

	Yes
	No